Background: Recent studies have revealed that liver metastasis is associated with poor
outcomes after treatment using immune checkpoint inhibitors, although the cause remains …

Purpose To conduct a retrospective multicenter trial to determine the significance of
metastatic site as a predictor of nivolumab efficacy in patients with advanced non-small cell …

Objectives Although liver metastasis has been known to be associated with poor prognosis,
only a few studies have shown an association between liver metastasis and treatment …

Liver Metastasis Is Associated with Poor Progression-Free Survival in Patients with Non-Small
Cell Lung Cancer Treated with Nivo Page 1 Liver Metastasis Is Associated with Poor …

Background Long-term data with immune checkpoint inhibitors in non-small-cell lung cancer
(NSCLC) are limited. Two phase III trials demonstrated improved overall survival (OS) and a …

Background: Nivolumab has shown promising effects in patients with non-small-cell lung
cancer (NSCLC) as a second-or later-line treatment. This study aimed to identify patients …

Background Response to immune checkpoint inhibitors depends on tumor intrinsic
properties and also on host factors in the tumour microenvironment including the presence …

Background The advent of immune checkpoint inhibitors (ICIs) has considerably expanded
the armamentarium against non-small cell lung cancer (NSCLC) contributing to reshaping …

Background: Immune-checkpoint inhibitors have radically changed the treatment landscape
of Non-Small-Cell Lung Cancer (NSCLC). It is still unclear whether specific clinical …

Introduction The prognosis of advanced non-small-cell lung cancer (NSCLC) has been
improved by development of immune checkpoint inhibitors (ICIs) such as nivolumab for …